These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

220 related articles for article (PubMed ID: 32710489)

  • 1. Genotype-phenotype correlation at codon 1740 of SETD2.
    Rabin R; Radmanesh A; Glass IA; Dobyns WB; Aldinger KA; Shieh JT; Romoser S; Bombei H; Dowsett L; Trapane P; Bernat JA; Baker J; Mendelsohn NJ; Popp B; Siekmeyer M; Sorge I; Sansbury FH; Watts P; Foulds NC; Burton J; Hoganson G; Hurst JA; Menzies L; Osio D; Kerecuk L; Cobben JM; Jizi K; Jacquemont S; Bélanger SA; Löhner K; Veenstra-Knol HE; Lemmink HH; Keller-Ramey J; Wentzensen IM; Punj S; McWalter K; Lenberg J; Ellsworth KA; Radtke K; Akbarian S; Pappas J
    Am J Med Genet A; 2020 Sep; 182(9):2037-2048. PubMed ID: 32710489
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Epigenotype-genotype-phenotype correlations in SETD1A and SETD2 chromatin disorders.
    Lee S; Menzies L; Hay E; Ochoa E; Docquier F; Rodger F; Deshpande C; Foulds NC; Jacquemont S; Jizi K; Kiep H; Kraus A; Löhner K; Morrison PJ; Popp B; Richardson R; van Haeringen A; Martin E; Toribio A; Li F; Jones WD; Sansbury FH; Maher ER
    Hum Mol Genet; 2023 Nov; 32(22):3123-3134. PubMed ID: 37166351
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical Heterogeneity and Different Phenotypes in Patients with
    Parra A; Rabin R; Pappas J; Pascual P; Cazalla M; Arias P; Gallego-Zazo N; Santana A; Arroyo I; Artigas M; Pachajoa H; Alanay Y; Akgun-Dogan O; Ruaud L; Couque N; Levy J; Porras-Hurtado GL; Santos-Simarro F; Ballesta-Martinez MJ; Guillén-Navarro E; Muñoz-Hernández H; Nevado J; Spanish OverGrowth Registry Initiative ; Tenorio-Castano J; Lapunzina P
    Genes (Basel); 2023 May; 14(6):. PubMed ID: 37372360
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mutation pattern and genotype-phenotype correlations of SETD2 in neurodevelopmental disorders.
    Chen M; Quan Y; Duan G; Wu H; Bai T; Wang Y; Zhou S; Ou J; Shen Y; Hu Z; Xia K; Guo H
    Eur J Med Genet; 2021 May; 64(5):104200. PubMed ID: 33766796
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Two novel cases expanding the phenotype of SETD2-related overgrowth syndrome.
    van Rij MC; Hollink IHIM; Terhal PA; Kant SG; Ruivenkamp C; van Haeringen A; Kievit JA; van Belzen MJ
    Am J Med Genet A; 2018 May; 176(5):1212-1215. PubMed ID: 29681085
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Case of Luscan-Lumish Syndrome: Possible Involvement of Enhanced GH Signaling.
    Suda K; Fukuoka H; Iguchi G; Kanie K; Fujita Y; Odake Y; Matsumoto R; Bando H; Ito H; Takahashi M; Chihara K; Nagai H; Narumi S; Hasegawa T; Ogawa W; Takahashi Y
    J Clin Endocrinol Metab; 2021 Mar; 106(3):718-723. PubMed ID: 33248444
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dual Chromatin and Cytoskeletal Remodeling by SETD2.
    Park IY; Powell RT; Tripathi DN; Dere R; Ho TH; Blasius TL; Chiang YC; Davis IJ; Fahey CC; Hacker KE; Verhey KJ; Bedford MT; Jonasch E; Rathmell WK; Walker CL
    Cell; 2016 Aug; 166(4):950-962. PubMed ID: 27518565
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical and genetic features of luscan-lumish syndrome associated with a novel de novo variant of
    Zhang Y; Zhang H; Wu W; Wang D; Lv Y; Zhao D; Wang L; Liu Y; Zhang K
    Front Genet; 2023; 14():1081391. PubMed ID: 36777730
    [No Abstract]   [Full Text] [Related]  

  • 9. Cellular and molecular functions of SETD2 in the central nervous system.
    Mitchell B; Thor S; Piper M
    J Cell Sci; 2023 Nov; 136(21):. PubMed ID: 37921122
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Benzene Hematotoxic and Reactive Metabolite 1,4-Benzoquinone Impairs the Activity of the Histone Methyltransferase SET Domain Containing 2 (SETD2) and Causes Aberrant Histone H3 Lysine 36 Trimethylation (H3K36me3).
    Berthelet J; Michail C; Bui LC; Le Coadou L; Sirri V; Wang L; Dulphy N; Dupret JM; Chomienne C; Guidez F; Rodrigues-Lima F
    Mol Pharmacol; 2021 Sep; 100(3):283-294. PubMed ID: 34266924
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A novel
    Wu Y; Liu F; Wan R; Jiao B
    Front Genet; 2023; 14():1153284. PubMed ID: 37025455
    [No Abstract]   [Full Text] [Related]  

  • 12. A New Chromatin-Cytoskeleton Link in Cancer.
    Giaccia AJ
    Mol Cancer Res; 2016 Dec; 14(12):1173-1175. PubMed ID: 27528705
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Novel USP9X variant associated with syndromic intellectual disability in a female: A case study and review.
    Meira JGC; Magalhães BS; Ferreira IBB; Tavares DF; Kobayashi GS; Leão EKEA
    Am J Med Genet A; 2021 May; 185(5):1569-1574. PubMed ID: 33638286
    [TBL] [Abstract][Full Text] [Related]  

  • 14. SETD2 related overgrowth syndrome: Presentation of four new patients and review of the literature.
    Marzin P; Rondeau S; Aldinger KA; Alessandri JL; Isidor B; Heron D; Keren B; Dobyns WB; Cormier-Daire V
    Am J Med Genet C Semin Med Genet; 2019 Dec; 181(4):509-518. PubMed ID: 31643139
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mutations in SETD2 cause a novel overgrowth condition.
    Luscan A; Laurendeau I; Malan V; Francannet C; Odent S; Giuliano F; Lacombe D; Touraine R; Vidaud M; Pasmant E; Cormier-Daire V
    J Med Genet; 2014 Aug; 51(8):512-7. PubMed ID: 24852293
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Novel unconventional variants expand the allelic spectrum of OPHN1 gene.
    Nuovo S; Brankovic V; Caputi C; Casella A; Nigro V; Leuzzi V; Valente EM
    Am J Med Genet A; 2021 May; 185(5):1575-1581. PubMed ID: 33638601
    [TBL] [Abstract][Full Text] [Related]  

  • 17.
    Tlemsani C; Luscan A; Leulliot N; Bieth E; Afenjar A; Baujat G; Doco-Fenzy M; Goldenberg A; Lacombe D; Lambert L; Odent S; Pasche J; Sigaudy S; Buffet A; Violle-Poirsier C; Briand-Suleau A; Laurendeau I; Chin M; Saugier-Veber P; Vidaud D; Cormier-Daire V; Vidaud M; Pasmant E; Burglen L
    J Med Genet; 2016 Nov; 53(11):743-751. PubMed ID: 27317772
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Molecular determinants for α-tubulin methylation by SETD2.
    Kearns S; Mason FM; Rathmell WK; Park IY; Walker C; Verhey KJ; Cianfrocco MA
    J Biol Chem; 2021 Jul; 297(1):100898. PubMed ID: 34157286
    [TBL] [Abstract][Full Text] [Related]  

  • 19. SETD2, an epigenetic tumor suppressor: a focused review on GI tumor.
    Hu M; Hu M; Zhang Q; Lai J; Liu X
    Front Biosci (Landmark Ed); 2020 Jan; 25(4):781-797. PubMed ID: 31585917
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Autosomal dominant inheritance in a recently described ZMIZ1-related neurodevelopmental disorder: Case report of siblings and an affected parent.
    Latchman K; Calder M; Morel D; Rhodes L; Juusola J; Tekin M
    Am J Med Genet A; 2020 Mar; 182(3):548-552. PubMed ID: 31833199
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.